LOGIN 

 

JOIN

 

RENEW

 

CME/MOC

Sleep Related Questionnaires

HomeMembersAssemblies and SectionsAssembliesSleep and Respiratory NeurobiologySleep Related Questionnaires ▶ Augmentation Severity Rating Scale (ASRS)
Augmentation Severity Rating Scale (ASRS)

Name of questionnaire Augmentation Severity Rating Scale (ASRS)
Type of questionnaire-description,age

Quantitative measure of augmentation severity (worsening of restless legs syndrome (RLS) symptoms during treatment).

To be used at baseline and then administered prospectively during treatment.
Number of items 3
Number of domains /categories 3
Name of categories/domains   Not applicable
Scaling of items 0-8 per item
Scoring available: with permission or free 0-24 0=no augmentation, 24= very severe augmentation
Scoring test-retest reliability Yes, rho=0.72
Scoring Internal consistency Yes, Cronbach's alpha = 0.62
Validity Yes, assessed by the correlation between the worst ASRS total score and the expert rating
Available forms (short and/or long etc.) N/A
Language English
Translations in other languages (if yes, then list the languages) Czech Dutch, Finnish, German, Italian, Polish, Spanish, Swedish
Developer name The European Restless Legs Syndrome Study Group (EURLSSG)
Developer contact information Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon, France
Telephone: +33 (0)4 72 13 65 75
Availability of questionnaire: needs permission from developer, cost or freely available

Use with permission from Mapi Research Trust
Free for students, physicians, clinical practice, non-funded academic users. Fees may apply for funded academic users, healthcare organizations, commercial users & IT companies.

Limitations Needs interviewer expertise-i.e. skilled clinician interpretation
Link to the questionnaire (if available) https://eprovide.mapi-trust.org/instruments/augmentation-severity-rating-scale
Other comments Baseline value must be obtained prior to therapy initiation. Subsequent assessments are compared to baseline value to determine presence/severity of augmentation (recommended cutoff score of 5 for augmentation)
Patient populations in who questionnaire has been validated Adult RLS patients aged 18-80 years
References (including original publication, validity and reliability in different countries/languages, populations and long/short versions)
  1. Garcia-Borreguero D, Kohnen R, Hogl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a muticentric, prospective study with levodopa on Restless Legs Syndrome. Sleep Med 2007;8:455–463.
  2. Garcia-Borreguero D, Allen RP, Kohnen R, et al. On behalf of the International Restless Legs Syndrome Study Group. Diagnostic standards for dopaminergic augmentation of Restless Legs Syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520–530.
  3. Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010;257(2):230-7.
  4. Trenkwalder C, Caelo M, Lang M, et al. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017;30:257-265.
Updated by Jing Wang, MD
The last date of update October 2022